Taxotere, a chemotherapy drug approved by the FDA for treating cancer in 1996, is currently the subject of several lawsuits in multiple states as the announcement hit the news that the first lawsuit filed under MDL 2740 Taxotere (Docetaxel) Products Liability Litigation is set for trial in September 2018. The allegations are against drug manufacturer Sanofi-Aventis, wherein the plaintiffs allege that they were deprived of making an informed decision to select other similar drugs which lacked the risk of alopecia. Another strong allegation faced by Sanofi-Aventis is that it failed to adequately warn female breast cancer patients and doctors about the risk of permanent baldness from Taxotere.
This July, the Taxotere Plaintiffs also filed a motion to remand certain cases to three different state courts in Missouri, California, and Delaware. The cases would be chosen from more than thousands of Taxotere lawsuits already filed. However, the Plaintiffs were ordered to file a written submission regarding this at a later date. The lawsuits are filed in the U.S. District Court, Eastern District of Louisiana and the women living with this agitable condition are looking forward to favorable court proceedings. The Plaintiff facts sheets are made officially available, lawyers can start prepping up the Taxotere cases, Neural IT understands SOLs deadlines and offers the required skill backed with the latest technology.